RecruitingPhase 2NCT07065240
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults With Major Depressive Disorder (MDD), With or Without Anxious Distress
Sponsor
Seaport Therapeutics
Enrollment
360 participants
Start Date
Jun 19, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria6
- Participant is a male or female between 18 and 65 years of age, inclusive willing and able and have capacity to provide written informed consent.
- Participants must have a primary diagnosis of MDD. Participants with a diagnosis of comorbid generalized anxiety disorder, social anxiety disorder, or panic disorder (with or without agoraphobia) may be included if not the focus of treatment over the past 6 months prior to Screening and the Investigator considers MDD to be the primary diagnosis at Screening and Baseline.
- Eligible participants must have a current depressive episode of at least 4 weeks, but no greater than 18 months in duration prior to Screening.
- Women of childbearing potential (WOCP) must not plan to become pregnant during the course of the study or be currently breastfeeding. WOCP agree to use an acceptable form of highly effective contraception during participation in the study and for 30 days after receiving the last dose of study treatment.
- Body mass index (BMI) between 18 to 40 kg/m2, inclusive.
- Participant is willing and able to refrain from the use of drugs of abuse.
Exclusion Criteria14
- History of, or current presentation consistent with:
- any depressive episode with psychotic or catatonic features.
- any bipolar manic, hypomanic or mixed episode, and substance-induced (e.g., antidepressant-induced) manic, hypomanic/mixed episode.
- bipolar disorder, including history of bipolar depression, or current presentation consistent with bipolar depression.
- schizophrenia, schizoaffective, or other psychotic disorder.
- obsessive-compulsive disorder.
- any persistent neurocognitive disorder.
- History of treatment-resistant depression defined as 2 or more failed treatments of adequate dose and duration in the current depressive episode.
- Psychiatric hospitalization within current depressive episode.
- Evidence or history of clinically significant diseases which can affect the patients' participation.
- Previous history of intolerance or significant adverse effects, including drug allergy to allopregnanolone or any components of the SPT-300/placebo formulation.
- Participant has a history of drug or alcohol use disorder.
- Participants with a positive test for cannabinoids.
- Clinically significant risk of suicide or harm to self or others.
Interventions
DRUGSPT-300
A prodrug of allopregnanolone, a small molecule drug
DRUGPlacebo
Placebo for SPT-300
Locations(45)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07065240
Related Trials
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT0679339767 locations
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
NCT073962721 location
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
NCT0730096924 locations
Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan
NCT070159441 location
Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders
NCT074797581 location